Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1 ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )

Results from the IMpassion130 trial for triple-negative breast cancer

Prof Peter Schmid - St Bartholomew Hospital London, UK

Results from the IMpassion130 trial for triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew Hospital London, UK )

Economics and education around biosimilars

Prof Arnold G. Vulto - Erasmus MC, Rotterdam, Netherlands

Economics and education around biosimilars ( Prof Arnold G. Vulto - Erasmus MC, Rotterdam, Netherlands )

Rare EGFR mutations in lung adenocarcinoma

Prof Nicolas Girard - Institut Curie, Paris, France

Rare EGFR mutations in lung adenocarcinoma ( Prof Nicolas Girard - Institut Curie, Paris, France )

New therapeutic options in advanced and metastatic breast cancer

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

New therapeutic options in advanced and metastatic breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )

In vitro diagnostic models for ALL: what can we learn on actionable targets?

Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland

In vitro diagnostic models for ALL: what can we learn on actionable targets? ( Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland )

Bispecific T-cell engaging therapy for adult ALL

Prof Max Topp - University of Würzburg, Würzburg, Germany

Bispecific T-cell engaging therapy for adult ALL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Optimal use of TKIs for therapy of Ph-positive ALL

Dr Josep Ribera - Catalan Institute of Oncology, Badalona, Spain

Optimal use of TKIs for therapy of Ph-positive ALL ( Dr Josep Ribera - Catalan Institute of Oncology, Badalona, Spain )

Management of MLL-rearranged ALL

Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht...

Management of MLL-rearranged ALL ( Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht, Netherlands )

Against HSCT in Ph-positive ALL

Prof Robin Foa - Professor of Haematology and Head of Haematology, University...

Against HSCT in Ph-positive ALL ( Prof Robin Foa - Professor of Haematology and Head of Haematology, University of Rome, Rome, Italy )

CAR-T cells: challenges and opportunities

Dr Sara Ghorashian - University College London, London, UK

CAR-T cells: challenges and opportunities ( Dr Sara Ghorashian - University College London, London, UK )

Editor’s Choice for September 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor’s Choice for September 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

More from ecancer